Trial · NCT04092452
Adverse events40
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
21 to 40 of 40
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hidradenitis | Skin and subcutaneous tissue disorders | Placebo | 2 | 48 | |
| other | Hidradenitis | Skin and subcutaneous tissue disorders | PF-06650833 400mg QD | 1 | 47 | |
| other | Hidradenitis | Skin and subcutaneous tissue disorders | PF-06700841 45mg QD | 1 | 52 | |
| other | Hidradenitis | Skin and subcutaneous tissue disorders | PF-06826647 400mg QD | 6 | 47 | |
| serious | COVID-19 | Infections and infestations | Placebo | 0 | 48 | |
| serious | COVID-19 | Infections and infestations | PF-06650833 400mg QD | 0 | 47 | |
| serious | COVID-19 | Infections and infestations | PF-06700841 45mg QD | 0 | 52 | |
| serious | COVID-19 | Infections and infestations | PF-06826647 400mg QD | 1 | 47 | |
| serious | Cellulitis | Infections and infestations | Placebo | 0 | 48 | |
| serious | Cellulitis | Infections and infestations | PF-06650833 400mg QD | 1 | 47 | |
| serious | Cellulitis | Infections and infestations | PF-06700841 45mg QD | 0 | 52 | |
| serious | Cellulitis | Infections and infestations | PF-06826647 400mg QD | 0 | 47 | |
| serious | Suicidal ideation | Psychiatric disorders | Placebo | 0 | 48 | |
| serious | Suicidal ideation | Psychiatric disorders | PF-06650833 400mg QD | 1 | 47 | |
| serious | Suicidal ideation | Psychiatric disorders | PF-06700841 45mg QD | 0 | 52 | |
| serious | Suicidal ideation | Psychiatric disorders | PF-06826647 400mg QD | 0 | 47 | |
| serious | Hidradenitis | Skin and subcutaneous tissue disorders | Placebo | 0 | 48 | |
| serious | Hidradenitis | Skin and subcutaneous tissue disorders | PF-06650833 400mg QD | 0 | 47 | |
| serious | Hidradenitis | Skin and subcutaneous tissue disorders | PF-06700841 45mg QD | 0 | 52 | |
| serious | Hidradenitis | Skin and subcutaneous tissue disorders | PF-06826647 400mg QD | 1 | 47 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04092452/events?page=2